MAPT and amyloidosis: Recently, plasma p-tau biomarkers (p-tau181, p-tau217, p-tau231) have been suggested to be valid indicators of amyloid and tau PET in clinical and community populations [10–16], although multiple comorbidities may affect the interpretation of these biomarkers [16].